Case report of embryonal rhabdomyosarcoma of the testis with an 8-year survival.
The low incidence of embryonal rhabdomyosarcoma prevents any one person or institution from presenting any meaningful data in the form of effective treatment based on clinical experience. We realize that this is an antidotal case but the stakes are high when treating any malignancy of the young. Therefore, we advocate early and aggressive therapy using all modalities of treatments, and cite this case which initially seemed hopeless but to date has all the hallmarks of a cure.
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003609:Dactinomycin / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D011379:Prognosis; D012075:Remission, Spontaneous; D012208:Rhabdomyosarcoma / Q000188:drug therapy* / Q000473:pathology; D013736:Testicular Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003609:Dactinomycin; D014750:Vincristine; D008727:Methotrexate